Browsing Tag
Bristol Myers Squibb
44 posts
Bristol Myers Squibb’s CD19 NEX-T therapy shows 94% off immunosuppressants in early Phase 1 results
Bristol Myers Squibb’s CAR T cell therapy shows early promise in autoimmune disorders. Find out what the data means for the stock and the wider market.
October 25, 2025
The in-vivo revolution: How pharma is racing to reprogram immunity inside the body
Explore how pharma giants like Bristol Myers Squibb are driving the in-vivo revolution to reprogram immunity and transform autoimmune and cancer care.
October 14, 2025
Can Bristol Myers Squibb’s $1.5bn Orbital deal make in-vivo CAR-T the next big breakthrough in autoimmune care?
Bristol Myers Squibb’s $1.5 B Orbital buyout bets on in-vivo CAR-T and RNA delivery to reshape autoimmune care. Find out what it means for BMY investors.
October 11, 2025
Analysts weigh Bristol Myers Squibb’s $1.5bn Orbital Therapeutics deal as a bold but risky pivot
Bristol Myers Squibb’s $1.5 billion acquisition of Orbital Therapeutics aims to advance in vivo CAR T for autoimmune diseases and strengthen its RNA platform.
October 11, 2025
What Sutro Biopharma’s restructuring says about biotech layoffs and investor sentiment in 2025
Sutro Biopharma (NASDAQ: STRO) slashes jobs and narrows its pipeline to extend cash runway into 2027. What does this restructuring mean for investors?
September 30, 2025
Sotyktu joins Eliquis in Bristol Myers’ direct-to-patient experiment — Is this the future of pharma distribution?
Bristol Myers Squibb adds Sotyktu to its DTC channel with 86% discount, reshaping drug pricing and patient access. See why this matters for pharma.
September 27, 2025
Why Bristol Myers Squibb is walking away from its first China joint venture after four decades
Bristol Myers Squibb’s 60% stake sale in its China JV shows a pivot from generics to innovation. Find out what this means for its stock and growth outlook.
September 17, 2025
LOTTE BIOLOGICS secures third major contract of 2025 through new U.S. biopharma manufacturing deal
LOTTE BIOLOGICS wins a third U.S. contract in 2025, boosting its CDMO momentum and investor sentiment. Find out how the deal shapes biomanufacturing strategy.
September 2, 2025
Innovent Biologics secures FDA greenlight for first global Phase 3 trial of IBI363 in lung cancer
Innovent Biologics wins FDA approval for its first global Phase 3 trial of IBI363 in lung cancer, signaling a major milestone in immuno-oncology.
August 25, 2025
Can Pfizer’s pipeline offset looming patent cliffs despite a stronger 2025 forecast?
Can Pfizer’s oncology and rare disease pipeline replace billions lost to patent cliffs? Explore how the drugmaker compares with Merck, Bristol Myers, and AstraZeneca.
August 20, 2025